Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The results that exceeded Wall Street expectations pushed the U.S. drugmaker's shares up nearly 13% in premarket trading, ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the ...

One man's trash may be another man's treasure, but dumpster diving when investing carries risks. You have to wade through a ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy Mounjaro, also based on tirzepatide, saying it was seeing the benefit ...

Lilly's move comes as Zepbound seems to be building momentum in the market – with second-quarter sales of $1.2 billion, way ahead of forecasts – at the same time as Novo Nordisk has reported ...